The National Institute of Health and Care Excellence (NICE) has set out new guidance for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within NHS England. The new guidance has been created to cover aspects of management where in the past there was uncertainty or variation…
DetailsThis study shows benefits from zoledronic acid monotherapy in myeloma patients with asymptomatic biochemical relapse and suggests that it should be considered as a new standard of care for this group.
DetailsThis study provides evidence that high-dose therapy and autologous stem cell transplantation performed in the outpatient setting can result in excellent outcomes for selected myeloma patients.
DetailsThe IMWG report on the newly developed revised version of the International Staging System (R-ISS) which incorporates chromosomal abnormalities to develop a more powerful staging system for stratifying myeloma patients.
The National Institute for Health and Care Excellence (NICE) has issued draft guidelines for consultation to improve the care of adults during the last few days of life. The guidelines are meant to replace the Liverpool Care Pathway which were phased out in 2014. Key recommendations highlight the importance of communication and shared decision-making involving…
DetailsThis study, based on data from the VISTA trial, showed that cumulative bortezomib dosage affects response rate, time-to-progression and overall survival.
DetailsThe International Myeloma Working Group (IMWG) has revised the International Staging System (ISS) to enable better stratification of newly diagnosed myeloma patients. It now includes the detection of chromosomal abnormalities (CA) by interphase fluorescent in situ hybridisation (iFISH) and the measurement of serum lactate dehydrogenase (LDH) which, when combined with the previous ISS, provides powerful…
DetailsMyeloma UK and the UK Spinal Myeloma Working Group have jointly published a paper on the optimal management of spinal disease in myeloma patients. Published in the British Journal of Haematology, the article provides an overview of the treatment and management options for spinal myeloma disease and highlights the role of defined pathways to enable the…
DetailsThis paper, produced by an expert panel of the International Myeloma Working Group (IMWG), provides consensus updates on the disease definition of myeloma which now include validated biomarkers in addition to the presence of the traditional ‘CRAB’ criteria.
Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma. Watanabe T et al. PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. Chhabra S et al. J…
Details